<p><sup>a</sup> Mutant→Mutant, Mutant→Wildtype, Wildtype→Mutant cases</p><p><sup>b</sup> Fisher’s exact test, two-sided <i>P</i> value</p><p><sup>c</sup> Two-sample t-test, two-sided <i>P</i> value</p><p><sup>d</sup> One WT→WT was not evaluable for overall response</p><p><sup>e</sup><i>P</i> value from analysis of CR/PR vs SD</p><p>Association of pre- and post-chemotherapy mutation patterns with clinicopathological features.</p
<p>Log Rank (Mantel-Cox) test showing that patients who harbor (a) overall <i>TP53</i> and oncogenic...
<p><i>TERT<sup>wt</sup></i> = <i>TERT</i> promoter wild-type; <i>TERT<sup>mut</sup></i> = <i>TER...
<p>(A) Three patients were included in the analysis: pt1 and pt2 displaying a pattern of direct evol...
<p><b>Abbreviations:</b> C1, + = tumor response ≥25% after cycle 1 chemotherapy, C1,— = tumour respo...
<p>Statistically significant p-values (<0.05) are in boldface</p>a<p>Number of patients with resista...
Changes in tumor DNA mutation status during chemotherapy can provide insights into tumor biology and...
<p>Representative chromatograms of (A) <i>PIK3CA E542K</i> in a MT→MT case HOB045, (B) <i>EGFR S768I...
<p><i>TERT<sup>wt</sup></i> = <i>TERT</i> promoter wild-type; <i>TERT<sup>mut</sup></i> = <i>TER...
†<p>CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.</...
<p><b>(A)</b> The mutational status of TP53 and KRAS and the time of developing distant metastasis. ...
<p><b>(a)</b> Per-individual numbers, sorted from high to low, of somatic mutations falling in ZF po...
<p><i>P<sup>1</sup></i> with regard to clinical response comparing CR+PR+SD versus PD</p><p><i>P<sup...
Cancers are characterized by somatic mutation arising from the interplay of mutagen exposure and def...
V600E mutation detection in daily clinical practice in patients with metastatic Colorectal Cancer (m...
<p>Left panel, Patient 1, clonal; right panel, Patient 2, independent. Each dot represents a HC shar...
<p>Log Rank (Mantel-Cox) test showing that patients who harbor (a) overall <i>TP53</i> and oncogenic...
<p><i>TERT<sup>wt</sup></i> = <i>TERT</i> promoter wild-type; <i>TERT<sup>mut</sup></i> = <i>TER...
<p>(A) Three patients were included in the analysis: pt1 and pt2 displaying a pattern of direct evol...
<p><b>Abbreviations:</b> C1, + = tumor response ≥25% after cycle 1 chemotherapy, C1,— = tumour respo...
<p>Statistically significant p-values (<0.05) are in boldface</p>a<p>Number of patients with resista...
Changes in tumor DNA mutation status during chemotherapy can provide insights into tumor biology and...
<p>Representative chromatograms of (A) <i>PIK3CA E542K</i> in a MT→MT case HOB045, (B) <i>EGFR S768I...
<p><i>TERT<sup>wt</sup></i> = <i>TERT</i> promoter wild-type; <i>TERT<sup>mut</sup></i> = <i>TER...
†<p>CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.</...
<p><b>(A)</b> The mutational status of TP53 and KRAS and the time of developing distant metastasis. ...
<p><b>(a)</b> Per-individual numbers, sorted from high to low, of somatic mutations falling in ZF po...
<p><i>P<sup>1</sup></i> with regard to clinical response comparing CR+PR+SD versus PD</p><p><i>P<sup...
Cancers are characterized by somatic mutation arising from the interplay of mutagen exposure and def...
V600E mutation detection in daily clinical practice in patients with metastatic Colorectal Cancer (m...
<p>Left panel, Patient 1, clonal; right panel, Patient 2, independent. Each dot represents a HC shar...
<p>Log Rank (Mantel-Cox) test showing that patients who harbor (a) overall <i>TP53</i> and oncogenic...
<p><i>TERT<sup>wt</sup></i> = <i>TERT</i> promoter wild-type; <i>TERT<sup>mut</sup></i> = <i>TER...
<p>(A) Three patients were included in the analysis: pt1 and pt2 displaying a pattern of direct evol...